Join
Live feed
·
INSIDERFilingvia Quantisnow
Fate Therapeutics Inc. logo

Chief R&D Officer Valamehr Bahram was granted 200,000 shares, increasing direct ownership by 127% to 358,069 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
FATE· Fate Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FATE (Fate Therapeutics Inc.) and more on Quantisnow.